Inoculation of the new coronavirus vaccine developed by the American pharmaceutical company Novabacs, which is the fourth type in Japan, began on the 26th in Nagaoka City, Niigata Prefecture.
Last month, the Ministry of Health, Labor and Welfare officially approved the use of a new coronavirus vaccine developed by the American pharmaceutical company Nuvaxovid for people over the age of 18.
This vaccine, which is the fourth type in Japan, has a different mechanism from Pfizer and Moderna, and the Ministry of Health, Labor and Welfare assumes that it can be inoculated to people who have allergic reactions with conventional vaccines.
On the 26th, vaccination with this vaccine began at the clinic in Nagaoka City for the first time in Niigata Prefecture, and nine people who had made reservations were vaccinated in turn.
A man in his thirties in Nagaoka City, who was vaccinated, said, "I chose the Novaxovid vaccine because I thought it was reliable. I'm glad I was able to get it at an early stage."
Dr. Masa Tamura of "Ale Home Clinic" said, "I think this vaccine is easily accepted by people who have been resistant to vaccination."
The clinic plans to vaccinate 1,000 Novaxovids by July.